NASDAQ:ANAB AnaptysBio (ANAB) Stock Price, News & Analysis $20.37 -2.17 (-9.63%) Closing price 08/7/2025 04:00 PM EasternExtended Trading$20.68 +0.31 (+1.55%) As of 08/7/2025 06:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About AnaptysBio Stock (NASDAQ:ANAB) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get AnaptysBio alerts:Sign Up Key Stats Today's Range$20.26▼$23.6750-Day Range$20.37▼$27.0052-Week Range$12.21▼$41.31Volume528,984 shsAverage Volume458,985 shsMarket Capitalization$598.47 millionP/E RatioN/ADividend YieldN/APrice Target$47.75Consensus RatingModerate Buy Company Overview AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California. Read More AnaptysBio Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks48th Percentile Overall ScoreANAB MarketRank™: AnaptysBio scored higher than 48% of companies evaluated by MarketBeat, and ranked 553rd out of 921 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingModerate Buy Consensus RatingAnaptysBio has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 6 buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageAnaptysBio has only been the subject of 4 research reports in the past 90 days.Read more about AnaptysBio's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for AnaptysBio are expected to grow in the coming year, from ($6.08) to ($5.36) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of AnaptysBio is -4.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of AnaptysBio is -4.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAnaptysBio has a P/B Ratio of 8.74. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted35.48% of the float of AnaptysBio has been sold short.Short Interest Ratio / Days to CoverAnaptysBio has a short interest ratio ("days to cover") of 16.1, which indicates bearish sentiment.Change versus previous monthShort interest in AnaptysBio has recently increased by 0.21%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAnaptysBio does not currently pay a dividend.Dividend GrowthAnaptysBio does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted35.48% of the float of AnaptysBio has been sold short.Short Interest Ratio / Days to CoverAnaptysBio has a short interest ratio ("days to cover") of 16.1, which indicates bearish sentiment.Change versus previous monthShort interest in AnaptysBio has recently increased by 0.21%, indicating that investor sentiment is decreasing. News and Social Media3.9 / 5News Sentiment1.04 News SentimentAnaptysBio has a news sentiment score of 1.04. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.39 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for AnaptysBio this week, compared to 5 articles on an average week.Search Interest3 people have searched for ANAB on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat Follows1 people have added AnaptysBio to their MarketBeat watchlist in the last 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, AnaptysBio insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $493,202.00 in company stock.Percentage Held by Insiders33.50% of the stock of AnaptysBio is held by insiders. A high percentage of insider ownership can be a sign of company health.Read more about AnaptysBio's insider trading history. Receive ANAB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AnaptysBio and its competitors with MarketBeat's FREE daily newsletter. Email Address ANAB Stock News HeadlinesAnaptysBio (ANAB) Q2 Revenue Jumps 103%August 6 at 10:06 PM | fool.comAnaptys Announces Second Quarter 2025 Financial Results and Provides Business UpdateAugust 6 at 4:15 PM | globenewswire.comBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. | Crypto 101 Media (Ad)IBD Rating Upgrades: AnaptysBio Shows Improved Price StrengthAugust 1, 2025 | msn.comJ.P. Morgan Keeps Their Buy Rating on AnaptysBio (ANAB)July 25, 2025 | theglobeandmail.comAnaptysBio Earns RS Rating UpgradeJuly 24, 2025 | msn.comAnaptysBio: Potential Promise, But Some Cause For SkepticismJuly 14, 2025 | seekingalpha.comAnaptysBio, Inc. (ANAB) stock price, news, quote & history – Yahoo ...July 11, 2025 | nz.finance.yahoo.comSee More Headlines ANAB Stock Analysis - Frequently Asked Questions How have ANAB shares performed this year? AnaptysBio's stock was trading at $13.24 at the start of the year. Since then, ANAB shares have increased by 53.9% and is now trading at $20.37. How were AnaptysBio's earnings last quarter? AnaptysBio, Inc. (NASDAQ:ANAB) announced its earnings results on Wednesday, August, 6th. The biotechnology company reported ($1.34) EPS for the quarter, beating analysts' consensus estimates of ($1.50) by $0.16. The biotechnology company earned $22.26 million during the quarter, compared to analysts' expectations of $11.55 million. AnaptysBio had a negative trailing twelve-month return on equity of 210.18% and a negative net margin of 107.66%. Is AnaptysBio buying back stock? AnaptysBio's Board of Directors authorized a stock buyback program on Monday, March 24th 2025, which authorizes the company to buy back $75,000,000 in shares, according to EventVestor. This means that the company could repurchase up to 13.1% of its shares through open market purchases. Shares buyback programs are often a sign that the company's board of directors believes its stock is undervalued. When did AnaptysBio IPO? AnaptysBio (ANAB) raised $60 million in an initial public offering (IPO) on Thursday, January 26th 2017. The company issued 4,000,000 shares at $14.00-$16.00 per share. Credit Suisse and Stifel acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers. Who are AnaptysBio's major shareholders? AnaptysBio's top institutional investors include HighMark Wealth Management LLC (0.50%), Moody Aldrich Partners LLC (0.20%), Bleakley Financial Group LLC (0.13%) and Assenagon Asset Management S.A. (0.06%). Insiders that own company stock include Ecor1 Capital, Llc, Daniel Faga, Paul F Lizzul, Eric J Loumeau, Hollings Renton, Dennis Mulroy and Dennis M Fenton. View institutional ownership trends. How do I buy shares of AnaptysBio? Shares of ANAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of AnaptysBio own? Based on aggregate information from My MarketBeat watchlists, some other companies that AnaptysBio investors own include Meta Platforms (META), NVIDIA (NVDA), Tesla (TSLA), Alibaba Group (BABA), Advanced Micro Devices (AMD), Moderna (MRNA) and Alphabet (GOOG). Company Calendar Last Earnings8/06/2025Today8/07/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ANAB CIK1370053 Webwww.anaptysbio.com Phone(858) 362-6295FaxN/AEmployees100Year Founded2005Price Target and Rating Average Price Target for AnaptysBio$47.75 High Price Target$90.00 Low Price Target$20.00 Potential Upside/Downside+134.4%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage10 Analysts Profitability EPS (Trailing Twelve Months)($4.85) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$145.23 million Net Margins-107.66% Pretax Margin-125.66% Return on Equity-210.18% Return on Assets-28.43% Debt Debt-to-Equity RatioN/A Current Ratio8.25 Quick Ratio8.25 Sales & Book Value Annual Sales$91.28 million Price / Sales6.56 Cash FlowN/A Price / Cash FlowN/A Book Value$2.33 per share Price / Book8.74Miscellaneous Outstanding Shares29,380,000Free Float19,538,000Market Cap$598.47 million OptionableOptionable Beta-0.20 Social Links (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:ANAB) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | SponsoredAltucher: Trump’s Great Gain is startingNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | SponsoredThe Day Silicon DiesThe Day China Left America's Supercomputers in the Dust In 200 seconds, China's quantum computer accomplish...The Oxford Club | SponsoredThis accelerated income plan is solving American's #1 retirement fearThe #1 fear in retirement today? Running out of money. That’s why income expert Tim Plaehn created a simple...Investors Alley | SponsoredFuturist Eric Fry says it will be a “Summer of Surge” for these three stocksWhat you don’t own matters just as much as what you do. That’s the thinking behind Eric Fry’s long-time strate...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AnaptysBio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AnaptysBio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.